No Result
View All Result
SUBMIT YOUR ARTICLES
  • Login
Tuesday, December 16, 2025
TheAdviserMagazine.com
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
No Result
View All Result
TheAdviserMagazine.com
No Result
View All Result
Home Market Research Economy

No Manufacturing Jolt from Tariffs

by TheAdviserMagazine
3 hours ago
in Economy
Reading Time: 4 mins read
A A
No Manufacturing Jolt from Tariffs
Share on FacebookShare on TwitterShare on LInkedIn


Writing on Facebook, AEI economist Mark Perry points to evidence that the tariffs imposed in April by the Trump Administration have not resulted in job creation for the manufacturing industry (Mark’s graph is recreated below for those of you who do not have access to Facebook. The solid red line indicates the day the tariffs were imposed).

Prima facie, this decline indicates the tariffs are not working to “bring back” jobs. 

Some folks have objected that this graph is deceptive. Truncating the Y-axis makes the decline appear worse than it is. This objection misses the point: the trend is negative. Trump et al predicted the trend would be positive; the tariffs were supposed to reverse this declining trend. They got the direction wrong.

A more reasonable objection is that it takes time for manufacturers to hire. Even six months in, there’s no particular reason to think that manufacturing hiring would suddenly jump. What about future hiring trends?

Fortunately, the Bureau of Labor Statistics publishes that data. The BLS publishes their Job Openings and Labor Turnover Survey (JOLTS). Job Openings (series IDJTS300000000000000JOL) would be an indicator of future hiring as firms need to post their jobs before they can hire people.

Since the tariffs were imposed, job openings are down, too. Excluding the post-pandemic recovery years (2021–2022, when openings and hirings were unusually high as firms ramped back up after the lockdowns), manufacturing job openings averaged 543,000 job openings per month in 2023 and 2024. In other words, over the past two years, approximately half a million open manufacturing jobs were listed each month. These were not necessarily new job openings; they were just unfulfilled jobs. The BLS doesn’t track how long job postings are up. Since Trump’s inauguration and the initial tariffs declared in February, job openings have averaged 410,000. In other words, there are approximately 130,000 fewer job openings in manufacturing since the tariffs were imposed than before. The fewer openings indicate that firms are slowing their hiring, not increasing it. (Note: these data are seasonally-adjusted. In theory, there shouldn’t be seasonal swings.)

As recently reported by the Wall Street Journal, China is merely shifting exports from the United States to other countries.  The US tariffs haven’t done much to reduce Chinese export share, and certainly aren’t doing anything to help increase US exports.  Indeed, these results indicate the “optimal tariff model,” invoked by certain members of this administration, such as Peter Navarro, to justify tariffs, likely doesn’t apply. The point here is that US tariffs do not seem to be improving US manufacturing in the global sphere.

Do these data prove that tariffs are failing? Not necessarily. To do a causal analysis would require far more data, time, and research. But they are indicative that the tariffs are failing to accomplish their (oft-contradictory) goals.

Why are the tariffs failing to accomplish these goals?  In theory, tariffs should shift jobs to the protected industries.  If these tariffs protect manufacturing, why aren’t jobs shifting there?  

The argument for tariffs to protect manufacturing relies on an assumption that the imports are of final goods and that the protected country has tariff-free access to intermediate goods (the goods used in manufacturing).  In 21st-century America, that assumption doesn’t hold.  According to Dartmouth University trade economist Doug Irwin, approximately 75% of US imports are these intermediate goods (Free Trade Under Fire (5th ed) Table 1.1, pg 14).  This means that tariffs raise the cost of manufacturing in the US, and thus make US manufacturing less competitive against both foreign imports and in the global market.  As Irwin explains:

“Any trade restriction that increases the price of an intermediate good raises the costs of production in downstream user industries with an adverse effect on employment in those industries. In other words, when domestic firms have to pay a premium on their productive inputs, particularly when they are competing with foreign rivals that do not pay those taxes, employment in those industries suffers” (ibid, pg 100, emphasis added).

But let us steel-man and consider what other factors could cause a similar pattern:

For one, these tariffs face legal challenges. As of this writing, a legal challenge to the tariffs has been argued before the Supreme Court (Trump v. VOS Selections, consolidated with Learning Resources v. Trump). These cases have been ongoing since the spring, with an initial challenge filed in April 2025 in the US Court of International Trade. Given the costs of hiring, firms may be hesitant to hire while this case is pending. It’s possible that a resolution in favor of Trump on tariffs could set off a hiring bonanza. A major problem I see with this argument: many of the plaintiffs in VOS are manufacturers themselves. It’d be odd that they are arguing against tariffs and, if the tariffs hold, they’ll just start hiring.

There may be other reasonable claims out there, but I cannot think of any (share in the comments if you have thoughts).



Source link

Tags: joltManufacturingTariffs
ShareTweetShare
Previous Post

Nifty’s long-term uptrend intact, but short-term trend turns cautious below 25,900: Vinay Rajani

Next Post

Down Arrow Button Icon

Related Posts

edit post
Market Talk – December 15, 2025

Market Talk – December 15, 2025

by TheAdviserMagazine
December 15, 2025
0

ASIA: The major Asian stock markets had a negative day today: • NIKKEI 225 decreased 668.44 points or -1.31% to...

edit post
Trump Loses in Indiana as the MAGA Civil War Rages On

Trump Loses in Indiana as the MAGA Civil War Rages On

by TheAdviserMagazine
December 15, 2025
0

The MAGA civil war intensified as POTUS Trump lost his battle to bully Indiana Republicans into redrawing their congressional districts....

edit post
Obamacare Enhanced Subsidies/Health “Care” Fixes, Expressed as Pentagon Units

Obamacare Enhanced Subsidies/Health “Care” Fixes, Expressed as Pentagon Units

by TheAdviserMagazine
December 15, 2025
0

In the spirit of the Friedman Unit1 as a metric for Iraq war progress (or in his case, what wound...

edit post
Trump Goes Hoover | Mises Institute

Trump Goes Hoover | Mises Institute

by TheAdviserMagazine
December 15, 2025
0

Donald Trump told Politico’s Dasha Burns that he gives the US economy an A+++++. He posted on Truth Social, “When...

edit post
Links 12/15/2025 | naked capitalism

Links 12/15/2025 | naked capitalism

by TheAdviserMagazine
December 15, 2025
0

Experiment to train rats to play Doom reaches a new level; rats can now shoot enemies — wraparound AMOLED screen...

edit post
Free Will Is Real (with Kevin Mitchell)

Free Will Is Real (with Kevin Mitchell)

by TheAdviserMagazine
December 15, 2025
0

0:37Intro. Russ Roberts: Today is November 12th, 2025, and my guest is neuroscientist Kevin Mitchell. His latest book is Free...

Next Post
edit post
Down Arrow Button Icon

Down Arrow Button Icon

edit post
Urogen Pharma – URGN: Die neue Medikation gegen Blasenkrebs sorgt für Momentum!

Urogen Pharma – URGN: Die neue Medikation gegen Blasenkrebs sorgt für Momentum!

  • Trending
  • Comments
  • Latest
edit post
How Long is a Last Will and Testament Valid in North Carolina?

How Long is a Last Will and Testament Valid in North Carolina?

December 8, 2025
edit post
How to Make a Valid Will in North Carolina

How to Make a Valid Will in North Carolina

November 20, 2025
edit post
In an Ohio Suburb, Sprawl Is Being Transformed Into Walkable Neighborhoods

In an Ohio Suburb, Sprawl Is Being Transformed Into Walkable Neighborhoods

December 14, 2025
edit post
Democrats Insist On Taxing Tips        

Democrats Insist On Taxing Tips        

December 15, 2025
edit post
Who Should I Choose as My Powers of Attorney?

Who Should I Choose as My Powers of Attorney?

December 6, 2025
edit post
8 Places To Get A Free Turkey for Thanksgiving

8 Places To Get A Free Turkey for Thanksgiving

November 21, 2025
edit post
2 Best AI Stocks to Buy in December

2 Best AI Stocks to Buy in December

0
edit post
No Manufacturing Jolt from Tariffs

No Manufacturing Jolt from Tariffs

0
edit post
Why is XRP price falling?

Why is XRP price falling?

0
edit post
10 January Fees That Hit Seniors Harder Than Anyone Else

10 January Fees That Hit Seniors Harder Than Anyone Else

0
edit post
Urogen Pharma – URGN: Die neue Medikation gegen Blasenkrebs sorgt für Momentum!

Urogen Pharma – URGN: Die neue Medikation gegen Blasenkrebs sorgt für Momentum!

0
edit post
Nifty’s long-term uptrend intact, but short-term trend turns cautious below 25,900: Vinay Rajani

Nifty’s long-term uptrend intact, but short-term trend turns cautious below 25,900: Vinay Rajani

0
edit post
2 Best AI Stocks to Buy in December

2 Best AI Stocks to Buy in December

December 16, 2025
edit post
10 January Fees That Hit Seniors Harder Than Anyone Else

10 January Fees That Hit Seniors Harder Than Anyone Else

December 16, 2025
edit post
The Return of “Easy” Real Estate Deals? 2026 Could Get Even Better

The Return of “Easy” Real Estate Deals? 2026 Could Get Even Better

December 16, 2025
edit post
Why is XRP price falling?

Why is XRP price falling?

December 16, 2025
edit post
Urogen Pharma – URGN: Die neue Medikation gegen Blasenkrebs sorgt für Momentum!

Urogen Pharma – URGN: Die neue Medikation gegen Blasenkrebs sorgt für Momentum!

December 16, 2025
edit post
Down Arrow Button Icon

Down Arrow Button Icon

December 16, 2025
The Adviser Magazine

The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.

CATEGORIES

  • 401k Plans
  • Business
  • College
  • Cryptocurrency
  • Economy
  • Estate Plans
  • Financial Planning
  • Investing
  • IRS & Taxes
  • Legal
  • Market Analysis
  • Markets
  • Medicare
  • Money
  • Personal Finance
  • Social Security
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • 2 Best AI Stocks to Buy in December
  • 10 January Fees That Hit Seniors Harder Than Anyone Else
  • The Return of “Easy” Real Estate Deals? 2026 Could Get Even Better
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclosures
  • Contact us
  • About Us

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.